Virtual Challenging Case Clinic: B-Cell Lymphomas

  • Delve into treatment paradigms, available therapies, and agents under development for various subtypes of B-cell lymphomas
  • Expert insights on particularly challenging patient cases submitted by actual attendees

john leonard

Course Director

John P. Leonard, MD
Senior Associate Dean for
Innovation and Initiatives
Executive Vice Chair,
Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York

Agenda

  • Welcome, Introductions, and
    Pre-session Survey
  • General Disease State and
    Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions,
    and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

Updates from ASCO and EHA

John P. Leonard, MD
Weill Cornell Medical College | New York, New York
Wednesday, August 12, 2020

Hodgkin Lymphoma

Jonathan Friedberg, MD, MMSc
University of Rochester Medical Center | Rochester, New York
Wednesday, September 9, 2020

T-cell Lymphoma

Kerry Savage, MD
University of British Columbia | Vancouver, British Columbia
Wednesday, October 14, 2020

Marginal Zone Lymphoma

Peter Martin, MD
Weill Cornell Medicine | New York, New York
Wednesday, November 11, 2020

Follicular Lymphoma

Jonathon Cohen, MD, MS
Winship Cancer Institute of Emory University | Atlanta, Georgia
Wednesday, December 9, 2020

Year in Review

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Wednesday, January 20, 2021

Recordings From Previous Webinars

Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on July 8, 2020

Transformed Lymphoma

Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on June 10, 2020

Diffuse Large B-cell Lymphoma

Mitchell Smith, MD, PhD
George Washington University | Washington, District of Columbia
Broadcast on May 13, 2020

CAR T-Cell Therapy

Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on April 8, 2020

Mantle Cell Lymphoma

Thomas Witzig, MD
Mayo Clinic | Rochester, Minnesota
Broadcast on March 11, 2020

Updates from ASH

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on February 19, 2020

Year in Review

Nathan Fowler, MD
MD Anderson Cancer Center | Houston, Texas
Broadcast on September 10, 2019

Transplant in NHL

Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on August 13, 2019

Updates in Lymphoma from ASCO, EHA, and ICML

Matthew Lunning, DO
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on July 9, 2019

CNS Lymphoma

Philip Bierman, MD
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on June 11, 2019

Chronic Lymphocytic Leukemia

William Wierda, MD, PhD
MD Anderson Cancer Center | Houston, TX
Broadcast on May 14, 2019

T-cell Lymphoma

Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on April 9, 2019

Transformed Follicular Lymphoma

Bruce Cheson, MD, FACP, FAAAS
Georgetown University Medical Center | Washington, District of Columbia
Broadcast on March 12, 2019

Target Audience
The target audience for this activity is clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
Learning Objectives
After completing this activity, participants should be better able to:
  • Assess best available evidence regarding treatment of indolent and aggressive B-cell lymphomas
  • Evaluate the clinical implications of emerging data regarding B-cell lymphoma treatment approaches
  • Plan strategies to address complicated B-cell lymphoma cases
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Disclosure Statement
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Contact Us

Questions? Please contact Bio Ascend by phone: 888-476-9129 or email: info@bioascend.com!

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.